8-K: Waters Corporation Exceeds Expectations in Q1 2025, Raises Full-Year Guidance

Waters Corporation reported strong Q1 2025 results, exceeding expectations with sales of $662 million and raising its full-year sales and EPS guidance.

Summary

• Waters Corporation announced its Q1 2025 financial results, with sales reaching $662 million, a 4% increase as reported and a 7% increase in constant currency compared to Q1 2024.
• GAAP EPS for Q1 2025 was $2.03, up from $1.72 in Q1 2024, while non-GAAP EPS was $2.25, a 2% increase inclusive of unfavorable foreign exchange impacts.
• The company is raising its full-year 2025 constant currency sales growth guidance to a range of +5.0% to +7.0%.
• Full-year 2025 reported sales growth is now expected to be in the range of +4.0% to +6.0%.
• The company is also raising its full-year 2025 non-GAAP EPS guidance to a range of $12.75 to $13.05, reflecting year-over-year growth of approximately +8% to +10%, and +10% to +12% on a constant currency basis.
• For Q2 2025, the company expects constant currency sales growth in the range of +5.0% to +7.0% and reported sales growth in the range of +4.0% to +6.0%.
• Q2 2025 non-GAAP EPS is expected to be in the range of $2.88 to $2.98, reflecting year-over-year growth of approximately +10% to +13%, and +12% to +15% on a constant currency basis.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong Q1 results and raised guidance, indicating confidence in the company's future performance. While there are mentions of potential risks, the overall tone is optimistic.

Positives

• Strong instrument growth of 11% in constant currency indicates healthy demand for Waters Corporation's products.
• The increase in full-year sales and EPS guidance suggests confidence in the company's future performance.
• Growth in Pharma and Industrial end markets demonstrates the company's ability to capitalize on key industry trends.
• The company's focus on operational excellence and swift actions to mitigate the impact of tariffs and policy changes are positive signs.
• The company's unique exposure to resilient, downstream applications is a positive factor.

Negatives

• Non-GAAP EPS growth of 2% in Q1 2025 is relatively modest, especially considering the 7% sales growth in constant currency.
• Unfavorable foreign exchange impacts negatively affected EPS growth by approximately five percentage points.
• The company mentions potential impacts of tariffs and supply chain challenges, which could pose risks to future performance.

Risks

• The company acknowledges risks and uncertainties related to future economic and market conditions.
• Tariffs and supply chain challenges could negatively impact the company's financial results.
• The company's ability to retain and attract customers in various geographies and market segments is subject to risks.
• The company's competitive positioning and technological capabilities are subject to risks.

Future Outlook

Waters Corporation is raising its full-year 2025 constant currency sales growth guidance to +5.0% to +7.0% and its full-year 2025 non-GAAP EPS guidance to $12.75 to $13.05. The company expects second quarter 2025 constant currency sales growth in the range of +5.0% to +7.0% and second quarter 2025 non-GAAP EPS to be in the range of $2.88 to $2.98.

Management Comments

• Dr. Udit Batra, President & CEO, stated that the company's first-quarter results exceeded expectations, driven by double-digit instrument growth, strength in pharma, and the continued traction of their innovative product portfolio.
• Dr. Batra also mentioned that the company is raising its full-year 2025 guidance due to its unique exposure to resilient, downstream applications and its steadfast commitment to operational excellence.
• Dr. Batra noted that swift operational actions, combined with improvements in foreign exchange, position the company well to mitigate the impact of recently announced tariffs and policy changes, reaffirming the expectation of delivering high single-digit adjusted EPS growth for the year.

Industry Context

Waters Corporation's strong Q1 2025 results and raised guidance suggest a positive outlook for the analytical instruments and separations technologies market. The company's growth in the Pharma and Industrial sectors aligns with the increasing demand for analytical solutions in these industries. The company's focus on operational excellence and mitigation of tariff impacts is crucial in the current global economic environment.

Comparison to Industry Standards

• Waters Corporation competes with companies like Agilent Technologies, Thermo Fisher Scientific, and Danaher in the analytical instruments market.
• Agilent Technologies reported Q1 2025 revenue of $1.69 billion, while Thermo Fisher Scientific reported Q1 2025 revenue of $10.71 billion.
• Waters Corporation's Q1 2025 revenue of $662 million is smaller than its larger competitors, but its growth rate of 7% in constant currency is competitive.
• The company's focus on specific end markets like Pharma and Industrial allows it to differentiate itself from competitors with broader product portfolios.
• The company's raised guidance for full-year 2025 suggests confidence in its ability to maintain its competitive position.

Stakeholder Impact

• Shareholders will likely react positively to the strong Q1 results and raised guidance.
• Employees may be motivated by the company's success and positive outlook.
• Customers may benefit from the company's continued innovation and focus on quality.
• Suppliers may see increased demand for their products and services.
• Creditors may view the company as a lower-risk borrower due to its strong financial performance.

Next Steps

• Waters Corporation will webcast its first quarter 2025 financial results conference call on May 6, 2025.
• Investors can listen to the call and see the accompanying slide presentation on the company's website.
• A replay of the conference call will be available through at least June 3, 2025.

Key Dates

Keywords

Waters Corporation, financial results, Q1 2025, sales growth, EPS, guidance, instruments, pharmaceutical, industrial, constant currency